Amgen to Pay Mass. General Hospital $186M to Settle Enbrel Royalty Dispute

BOSTON - California-based drugmaker Amgen Inc. has agreed to pay Massachusetts General Hospital $186 million to settle a dispute over royalties the hospital was paid for its role in the development of the rheumatoid arthritis and psoriasis drug Enbrel.

With the one-time payment, Amgen will have no further obligation to pay royalties to MGH from North American sales of Enbrel, the company said on June 6.

The hospital will continue to earn royalties on sales of the drug outside North America, MGH stated in its own June 6 news release.

Combined Enbrel royalties accounted for almost $65 million of the …